An Update in Management of Noncutaneous T-Cell Lymphomas

Table 1

Summary of various treatment results of T-cell lymphomas.

Author	Year	No. of patients	ALK + ve ALCL	Regimens	CR	ORR	OS	EFS	Ref
Lopez-Guillermo et al.	1998	174	30 (ALK status not known)	120 CHOP 54 not specified	49%	64%	38%; (at 4 years)	Not available	[4]
Armitage et al.	1989	134	Not known	80 CHOP-like 54 not specified	50%	Not available	45%; (at 4 years)	Not available	[12]
Rudiger et al.	2002	129	0	90 CHOP-like 39 not specified	Not available	Not available	26%; (at 5 years)	20%; (at 5 years)	[13]
Schmitz et al.	2010	343	78	122 CHOP 221 CHOEP	Not available	Not available	53.9%–67.5%; (at 3 years)	41.1%–50.0%; (at 3 years)	[14]
Mourad et al.	2008	157	0	ACVBP + CHOP-like regimens	46%	Not available	33%; (at 5 years)	29%; (at 5 years)	[5]
Escalon et al.	2005	24	0	CHOP	58%	Not available	43%; (at 3 years)	Not available	[15]
Escalon et al.	2005	52	0	HyperCVAD like	59%	Not available	49%; (at 3 years)	Not available	[15]